Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000154906 | SCV000204588 | uncertain significance | not specified | 2013-10-10 | criteria provided, single submitter | clinical testing | The Ile26100Thr variant in TTN has not been reported in individuals with cardiom yopathy but has been identified in 1/3766 African American chromosomes by the NH LBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/). Computational analyses (biochemical amino acid properties, conservation, AlignGVGD, and SIFT) do not provide strong support for or against an impact to the protein. Additiona l information is needed to fully assess the clinical significance of the Ile2610 0Thr variant. |
Labcorp Genetics |
RCV000477626 | SCV000542422 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-12-05 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000733310 | SCV000861359 | uncertain significance | not provided | 2018-05-23 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000768882 | SCV000900255 | uncertain significance | Cardiomyopathy | 2017-10-30 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000733310 | SCV001764332 | likely benign | not provided | 2020-10-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002354369 | SCV002651813 | likely benign | Cardiovascular phenotype | 2020-03-03 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |